Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
Completed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin
(ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult
participants with recurrent glioblastoma. The study also included a substudy to evaluate
safety, tolerability and pharmacokinetics of ABT-414 in a pediatric population.
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
Completed
AbbVie
Phase 2
This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin
(ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult
participants with recurrent glioblastoma. The study also included a substudy to evaluate
safety, tolerability and pharmacokinetics of ABT-414 in a pediatric population.
UNITE Study: Understanding New Interventions With GBM ThErapy
Terminated
AbbVie
Phase 3
The objective of this study was to evaluate the effect of several ophthalmologic prophylactic
treatment strategies for the management of ocular side effects (OSEs) in participants with
epidermal growth factor receptor (EGFR)-amplified glioblastoma (GBM) who were being treated
with depatuxizumab mafodotin (ABT-414).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
